Evidence review

BPC-157: The Evidence, the Regulatory Position, and Why the Two Diverge

BPC-157 is not an approved drug anywhere. The FDA's compounding advisory committee reviewed it in July 2026 with briefing documents recommending against adding it to the

What it is

BPC-157 is a synthetic peptide derived from a sequence identified in gastric juice. It is marketed for tissue repair, tendon and ligament recovery, and gastrointestinal healing.

It has never been approved as a drug in the United States or elsewhere.

The evidence, separated by tier

Animal data. This is the bulk of what exists, and much of it is genuinely interesting — rodent models showing accelerated tendon and ligament healing, gastrointestinal protective effects, and angiogenic activity.

Human randomised trials with hard endpoints. Essentially absent. This is the gap that matters, and no amount of animal work substitutes for it.

Animal models are where drug development starts, not where it ends. The attrition rate between promising rodent data and demonstrated human benefit is very high across all of pharmacology, and a compound that has not made that transition after years of interest has not yet earned the claims made for it.

The regulatory position changed on 23 July 2026

This section was materially wrong two days ago and is corrected here, because the direction of travel reversed between the briefing documents and the vote.

What FDA staff said. Agency reviewers recommended against adding all seven peptides under review. For TB-500 they reported being unable to identify a single human clinical study. On BPC-157 the briefing package cited a lack of evidence supporting effectiveness for ulcerative colitis, the indication under review.

What the committee did. Across 23–24 July 2026 the Pharmacy Compounding Advisory Committee recommended six of the seven substances under review — BPC-157, KPV and TB-500 at 8–6 with one abstention, MOTS-c at 7–5 with two, semax at 8–5 and epitalon at 7–5 with one. Only emideltide was rejected, at 6–7. It overrode its own agency's scientists on every substance it recommended. Reporters in the room described an audible reaction when the tally was read.

All eight of the committee's newly added temporary members voted in favour on the first three; six other members voted against and one abstained. The committee has faced scrutiny over members with conflicts of interest.

Two facts that change how to read this

These are indication-specific. Each substance was reviewed against one proposed use, not for blanket compounding. BPC-157 was reviewed for ulcerative colitis — not for tendon or joint recovery, which is what drives nearly all of its consumer demand. TB-500 was reviewed for wound healing. Compounding either for a sports injury would fall outside the reviewed indication even after a listing.

All seven came off Category 2 on 23 April 2026. That reclassification — removal from the list of substances that may not be compounded — is what made this review possible. The July votes were never a re-ban risk; the only question was whether a new lawful channel opens. Coverage framing this as peptides surviving a threat has the direction backwards.

What the vote does not do

Three distinct legal events are being treated as one across most coverage, and the distinction decides what is lawful today.

1. Removal from Category 2 — the list of substances FDA has flagged with significant safety concerns.
2. A PCAC recommendation — what happened on 23 July. Non-binding.
3. Placement on the Category 1 compoundable list — requires formal notice-and-comment rulemaking, which commonly takes 8 to 12 months.

Only the third makes compounding lawful. The FDA is not bound by the recommendation and has gone against this committee before. In 2023 the agency reviewed a batch of popular peptides and declined to add them, stating they may present significant safety risks — which is what pushed these compounds into the grey market they have occupied since.

So nothing changed legally on 23 July. What changed is the probability of a future change, and the market has spent two days reacting as though the two were the same thing.

What you are actually buying

Most BPC-157 sold to consumers carries "research use only" or "not for human consumption" labelling. That labelling is not a formality or a legal fiction to be ignored; it is the seller stating the product's regulatory status accurately.

Practically, it means there is no prescriber, no licensed pharmacy, no verifiable potency or sterility testing, and no recourse if something goes wrong. Purity, dose accuracy and contamination are unverifiable by the purchaser.

The honest summary

There is a plausible mechanistic story and a body of animal work that would justify human trials. There are no human trials of the kind that would justify the claims being made. And the regulatory direction is toward closing rather than opening the compounding route.

Anyone presenting BPC-157 as an established therapy is describing a compound that has not completed the process by which therapies become established.

Questions readers actually ask